Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)

Abstract

The authors did not declare a relevant conflict of interest thus wish to publish a correction to add this: Compliance with ethical standards Conflict of interest JQL, CKO and STL are co-inventors of the patent filed under International Application No. PCT/SG2018/050509 by Singapore Health Services Pte Ltd which is related to this work. At the time of writing, the co-inventors did not receive honoraria for this work. The patent has been licensed to Lucence (did not take part in this study).